DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

8 API Suppliers, 4 USDMF, 2 EU WC, 3 NDC API, 2 Listed Suppliers, $ API Reference Price

8 API Suppliers
4 USDMF
2 EU WC
3 NDC API
2 Listed Suppliers
$ API Reference Price

FINISHED DOSAGE FORMULATIONS

25 FDF Dossiers, 23 Europe, 2 Listed Dossiers

25 FDF Dossiers
23 Europe
2 Listed Dossiers

RELATED EXCIPIENT COMPANIES

7 DKSH, 1 Faran Shimi Pharmaceutical, 4 Boai NKY Pharmaceuticals Ltd, 1 Gangwal Healthcare, 1 Alcedo Pharmachem, 2 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 6 BASF, 4 Gangwal Chemicals, 2 Kerry, 6 Microlex e.U, 1 Novo Excipients, 1 Pharmatrans-Sanaq, 1 Pluviaendo, 1 Prachin Chemical, 1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Ulanqab Kema New Material, 1 Vasa Pharmachem

relatedExcipients
7 DKSH
1 Faran Shimi Pharmaceutical
4 Boai NKY Pharmaceuticals Ltd
1 Gangwal Healthcare
1 Alcedo Pharmachem
2 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
6 BASF
4 Gangwal Chemicals
2 Kerry
6 Microlex e.U
1 Novo Excipients
1 Pharmatrans-Sanaq
1 Pluviaendo
1 Prachin Chemical
1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd
1 Ulanqab Kema New Material
1 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

15 Fillers, Diluents & Binders, 13 Disintegrants & Superdisintegrants, 8 Lubricants & Glidants, 8 Direct Compression, 5 Granulation, 4 Chewable & Orodispersible Aids, 4 Thickeners and Stabilizers, 4 Solubilizers, 2 Co-Processed Excipients, 2 Coating Systems & Additives, 2 Controlled & Modified Release, 1 Emulsifying Agents, 1 Taste Masking, 1 Film Formers & Plasticizers

excipientsByApplications
15 Fillers, Diluents & Binders
13 Disintegrants & Superdisintegrants
8 Lubricants & Glidants
8 Direct Compression
5 Granulation
4 Chewable & Orodispersible Aids
4 Thickeners and Stabilizers
4 Solubilizers
2 Co-Processed Excipients
2 Coating Systems & Additives
2 Controlled & Modified Release
1 Emulsifying Agents
1 Taste Masking
1 Film Formers & Plasticizers

GLOBAL SALES INFORMATION

23 Finished Drug Prices

globalSalesInformation
23 Finished Drug Prices

MARKET PLACE

6 APIs

marketPlace
6 APIs

REF. STANDARDS & IMPURITIES

1 USP , 1 Others

otherSolutions
1 USP
1 Others

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 4

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

41 RELATED EXCIPIENT COMPANIES

70EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 1317-26-6, Aluminum hydroxide/magnesium hydroxide, Aluminum hydroxide/magnesium hydroxide - magaldrate c410, Aluminum hydroxide/magnesium hydroxide - magaldrate c632

Molecular Formula

AlH₃MgO₂-

Molecular Weight

86.310 g/mol

InChI Key

SXSTVPXRZQQBKQ-UHFFFAOYSA-M

Aluminum Hydroxide/Magnesium Hydroxide is an oral suspension containing aluminum hydroxide and magnesium hydroxide, with antacid effects. Aluminum hydroxide and magnesium hydroxide neutralizes or reduces gastric acid, thereby relieving symptoms associated with indigestion, gastritis, and gastroesophageal disease (GERD). Combined with other liquid ingredients (such as lidocaine and diphenhydramine), this antacid provides relief for painful stomatitis, mucositis, and esophagitis associated with both chemotherapy and radiation therapy.

1 2D Structure

Magaldrate

2 Identification

2.1 Computed Descriptors

2.1.1 InChI

InChI=1S/Al.Mg.2H2O/h;;2*1H2/p-1

2.1.2 InChI Key

SXSTVPXRZQQBKQ-UHFFFAOYSA-M

2.1.3 Canonical SMILES

O.[OH-].[Mg].[Al]

2.2 Synonyms

2.2.1 Depositor-Supplied Synonyms

1. 1317-26-6

2. Aluminum Hydroxide/magnesium Hydroxide

3. Aluminum Hydroxide/magnesium Hydroxide - Magaldrate C410

4. Aluminum Hydroxide/magnesium Hydroxide - Magaldrate C632

2.3 Create Date

2005-08-08

3 Chemical and Physical Properties

Molecular Formula	AlH₃MgO₂-
Molecular Weight	86.310 g/mol
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	2
Rotatable Bond Count	0
Exact Mass	85.9798844 g/mol
Monoisotopic Mass	85.9798844 g/mol
Topological Polar Surface Area	2 Å²
Heavy Atom Count	4
Formal Charge	-1
Complexity	0
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	4

4 Pharmacology and Biochemistry

4.1 ATC Code

A02AD02

S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355

API SUPPLIERS